|Bid||84.90 x 800|
|Ask||85.70 x 1800|
|Day's Range||83.45 - 85.78|
|52 Week Range||51.05 - 135.59|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 30, 2018 - Aug 3, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||106.69|
NEW YORK, NY / ACCESSWIRE / June 20, 2018 / U.S. equities slumped on Tuesday as global trade concerns grew after President Trump threatened to impose an additional $400 billion in tariffs on goods from ...
NEW YORK, NY / ACCESSWIRE / June 13, 2018 / U.S. markets were relatively quiet following the summit between President Donald Trump and North Korean leader Kim Jong Un in Singapore. The Dow Jones Industrial ...
NEW YORK, NY / ACCESSWIRE / June 11, 2018 / TapImmune and Intercept Pharmaceuticals were two biotech stocks heading higher in Friday trading. Intercept didn't have any particularly remarkable news but did announce that management would be presenting this Tuesday at the Goldman Sachs 39th Annual Global Healthcare Conference.
NEW YORK, June 07, 2018-- Intercept Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, ...
Intercept (ICPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Biotech stocks are one of the hottest sectors in the stock market, as measured by the SPDR S&P Biotech ETF ( XBI). If the sector is to continue to rise, it will take stocks such as Spark Therapeutics Inc. ( ONCE), Intercept Pharmaceuticals Inc. ( ICPT), and Seattle Genetics Inc. ( SGEN) to help it rise.
Madrigal Pharmaceuticals' (MDGL) thyroid hormone receptor, MGL-3196, achieves significantly sustained reduction in liver fat at week 36 in a phase II study evaluating it in NASH patients.
Viking Therapeutics’ (VKTX) stock price rose ~101% on May 31 following the successful trial results of Madrigal Pharmaceuticals’ (MDGL) NASH drug. Madrigal Pharmaceuticals’ drug has a similar mechanism of action as Viking Pharmaceuticals’ NASH drug. In this part, we’ll discuss Wall Street analysts’ recommendations for Viking Therapeutics stock in the next 12 months.
Madrigal Pharmaceuticals, the biotech company based in West Conshohocken, Pennsylvania, saw its share price rise more than 150% today after announcing a successful completion of its Phase II clinical trial to reduce nonalcoholic steatohepatitis (NASH). NASH, also known as fatty liver disease, is a disorder related to obesity and is steadily gaining prevalence throughout the developing world.
Madrigal Pharmaceuticals Inc. more than doubled after a study of its new drug for a disease linked to obesity exceeded investor expectations. The results from a mid-stage study of the fatty liver disease known as nonalcoholic steatohepatitis, or NASH, also pushed small-cap peer Viking Therapeutics Inc. higher while shares of Intercept Pharmaceuticals Inc., a drugmaker further along in NASH development, slid. Patients getting Madrigal’s experimental therapy known as MGL-3196 had a two-point reduction in a score that measures disease activity with a liver biopsy.
The race is on to identify the wonder drug that will treat an increasingly common consequence of obesity: the fatty liver disease known as nonalcoholic steatohepatitis, or NASH. Madrigal Pharmaceuticals Inc. is expected to report results from a mid-stage study in NASH by Thursday. The drug developer is racing against peers like Intercept Pharmaceuticals Inc. to get its experimental therapy known as MGL-3196 to the market.
NEW YORK, May 18, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of AG ...
Biotech stocks are breaking out, with the SPDR S&P Biotech ETF ( XBI) gearing up for what could be a significant rise higher. Since that time the group has turned higher, and now technical analysis suggests more gains may lie ahead for the sector.
Intercept's (ICPT) first-quarter results were mixed as loss was narrower than expectations but sales missed expectations. The company also provided Ocaliva sales guidance for 2018.
The New York-based company said it had a loss of $3.22 per share. The results topped Wall Street expectations. The average estimate of eight analysts surveyed by Zacks Investment Research was for a loss ...
Intercept Pharmaceuticals, Inc. (ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced its financial results for the quarter ended March 31, 2018. “We are pleased with our progress to date in 2018, as we continue to work to strengthen our leadership position in NASH and remain on track for the top line readout of data from our Phase 3 REGENERATE trial in the first half of 2019. Based on our review of the evolving competitive landscape, the new data released at the recent International Liver Congress in Paris and the strength of OCA’s Phase 2 and other data, we continue to believe in OCA’s significant potential in NASH,” said Mark Pruzanski, M.D., President and Chief Executive Officer of Intercept.
NEW YORK, May 01, 2018-- Intercept Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, ...
Amicus Therapeutics (FOLD) is a global patient-focused biotechnology company engaged in developing and commercializing diverse novel treatments for patients with rare metabolic diseases. As of April 2018, of the seven analysts covering Amicus Therapeutics, three have given the stock “strong buy” ratings, three have given it “buy” ratings, and one has given it a “hold” rating. The mean rating for the stock is 1.71 with a target price of $19.93, implying an upside of almost 45% to $13.79 as of its closing on April 24.
NEW YORK, April 24, 2018-- Intercept Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, ...